IT201700058311A1 - Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini - Google Patents

Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Info

Publication number
IT201700058311A1
IT201700058311A1 IT102017000058311A IT201700058311A IT201700058311A1 IT 201700058311 A1 IT201700058311 A1 IT 201700058311A1 IT 102017000058311 A IT102017000058311 A IT 102017000058311A IT 201700058311 A IT201700058311 A IT 201700058311A IT 201700058311 A1 IT201700058311 A1 IT 201700058311A1
Authority
IT
Italy
Prior art keywords
vitamin
bacterial
ester
treatment
formulation based
Prior art date
Application number
IT102017000058311A
Other languages
English (en)
Inventor
Giorgio Panin
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Priority to IT102017000058311A priority Critical patent/IT201700058311A1/it
Priority to EA201992190A priority patent/EA201992190A1/ru
Priority to PCT/EP2018/063926 priority patent/WO2018219862A1/en
Priority to HRP20220808TT priority patent/HRP20220808T1/hr
Priority to AU2018275487A priority patent/AU2018275487B2/en
Priority to EP18727014.5A priority patent/EP3630092B1/en
Priority to CA3061568A priority patent/CA3061568C/en
Priority to DK18727014.5T priority patent/DK3630092T3/da
Priority to US16/613,526 priority patent/US20200360339A1/en
Priority to RS20220631A priority patent/RS63347B1/sr
Priority to MX2019013559A priority patent/MX2019013559A/es
Priority to LTEPPCT/EP2018/063926T priority patent/LT3630092T/lt
Priority to PL18727014.5T priority patent/PL3630092T3/pl
Priority to BR112019023962A priority patent/BR112019023962A8/pt
Priority to SI201830680T priority patent/SI3630092T1/sl
Priority to CN201880027971.1A priority patent/CN110650737A/zh
Priority to HUE18727014A priority patent/HUE059185T2/hu
Priority to GEAP201815201A priority patent/GEP20207179B/en
Priority to MA48936A priority patent/MA48936B1/fr
Priority to PT187270145T priority patent/PT3630092T/pt
Priority to ES18727014T priority patent/ES2919423T3/es
Publication of IT201700058311A1 publication Critical patent/IT201700058311A1/it
Priority to CL2019003254A priority patent/CL2019003254A1/es
Priority to US16/683,684 priority patent/US11234958B2/en
Priority to US17/231,761 priority patent/US20210228541A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
IT102017000058311A 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini IT201700058311A1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
LTEPPCT/EP2018/063926T LT3630092T (lt) 2017-05-29 2018-05-28 Kompozicija, kurios pagrindą sudaro vitaminas e arba jo esteris, skirta bakterijų ir grybelių bioplėvelėms gydyti
GEAP201815201A GEP20207179B (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or ester thereof for treating bacterial and fungal biofilms
HRP20220808TT HRP20220808T1 (hr) 2017-05-29 2018-05-28 Formulacija na bazi vitamina e ili njegovog estera za liječenje bakterijskih i gljivičnih biofilmova
AU2018275487A AU2018275487B2 (en) 2017-05-29 2018-05-28 Formulation based on vitamin E or an ester thereof for treating bacterial and fungal biofilms
EP18727014.5A EP3630092B1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
CA3061568A CA3061568C (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
DK18727014.5T DK3630092T3 (da) 2017-05-29 2018-05-28 Formulering på basis af vitamin E eller en ester deraf til behandling af bakterie- og svampebiofilm
US16/613,526 US20200360339A1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
RS20220631A RS63347B1 (sr) 2017-05-29 2018-05-28 Formulacija na bazi vitamina e ili njegovog estra za lečenje bakterijskih i gljivičnih biofilmova
MX2019013559A MX2019013559A (es) 2017-05-29 2018-05-28 Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas.
EA201992190A EA201992190A1 (ru) 2017-05-29 2018-05-28 Состав на основе витамина е или его сложного эфира для лечения бактериальных и грибковых биопленок
PL18727014.5T PL3630092T3 (pl) 2017-05-29 2018-05-28 Preparat na bazie witaminy e lub jej estru do leczenia biofilmów bakteryjnych i grzybiczych
CN201880027971.1A CN110650737A (zh) 2017-05-29 2018-05-28 基于维生素e或其酯的用于处理细菌和真菌生物膜的制剂
SI201830680T SI3630092T1 (sl) 2017-05-29 2018-05-28 Formulacija na osnovi vitamina E ali njegovega estra za tretiranje bakterijskih in glivičnih biofilmov
BR112019023962A BR112019023962A8 (pt) 2017-05-29 2018-05-28 Formulação à base de vitamina e ou um éster da mesma para tratamento de biofilmes bacterianos e fúngicos
HUE18727014A HUE059185T2 (hu) 2017-05-29 2018-05-28 Készítmény, amely e vitaminon vagy észteren alapul bakteriális vagy gomba eredetû biofilmek kezelésére
PCT/EP2018/063926 WO2018219862A1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
MA48936A MA48936B1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques
PT187270145T PT3630092T (pt) 2017-05-29 2018-05-28 Formulação à base de vitamina e ou um éster da mesma para tratar biofilmes bacterianos e fúngicos
ES18727014T ES2919423T3 (es) 2017-05-29 2018-05-28 Formulación basada en vitamina E o un éster de la misma para tratar biopelículas bacterianas o fúngicas
CL2019003254A CL2019003254A1 (es) 2017-05-29 2019-11-13 Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.
US16/683,684 US11234958B2 (en) 2017-05-29 2019-11-14 Formulation based on vitamin E or an ester thereof for treating bacterial and fungal biofilms
US17/231,761 US20210228541A1 (en) 2017-05-29 2021-04-15 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Publications (1)

Publication Number Publication Date
IT201700058311A1 true IT201700058311A1 (it) 2018-11-29

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Country Status (22)

Country Link
US (3) US20200360339A1 (it)
EP (1) EP3630092B1 (it)
CN (1) CN110650737A (it)
AU (1) AU2018275487B2 (it)
BR (1) BR112019023962A8 (it)
CA (1) CA3061568C (it)
CL (1) CL2019003254A1 (it)
DK (1) DK3630092T3 (it)
EA (1) EA201992190A1 (it)
ES (1) ES2919423T3 (it)
GE (1) GEP20207179B (it)
HR (1) HRP20220808T1 (it)
HU (1) HUE059185T2 (it)
IT (1) IT201700058311A1 (it)
LT (1) LT3630092T (it)
MA (1) MA48936B1 (it)
MX (1) MX2019013559A (it)
PL (1) PL3630092T3 (it)
PT (1) PT3630092T (it)
RS (1) RS63347B1 (it)
SI (1) SI3630092T1 (it)
WO (1) WO2018219862A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US6280752B1 (en) * 1998-09-25 2001-08-28 Giorgio Panin Vitamin E acetate-based hydrophobic gel formulation for topical application
WO2010121081A1 (en) * 2009-04-15 2010-10-21 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
WO2017050668A1 (en) * 2015-09-25 2017-03-30 Bio.Lo.Ga. S.R.L. Hydrophobic gel based on vitamin e free from silicone products for topical application
WO2017119009A1 (en) * 2016-01-08 2017-07-13 Eon Medica S.R.L. Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US6280752B1 (en) * 1998-09-25 2001-08-28 Giorgio Panin Vitamin E acetate-based hydrophobic gel formulation for topical application
WO2010121081A1 (en) * 2009-04-15 2010-10-21 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
WO2017050668A1 (en) * 2015-09-25 2017-03-30 Bio.Lo.Ga. S.R.L. Hydrophobic gel based on vitamin e free from silicone products for topical application
WO2017119009A1 (en) * 2016-01-08 2017-07-13 Eon Medica S.R.L. Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIDE CAMPOCCIA ET AL: ")lactic acid blended with vitamin E: Toward gentle anti-infective biomaterials", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART A, vol. 103, no. 4, 4 August 2014 (2014-08-04), HOBOKEN, NY, US, pages 1447 - 1458, XP055303081, ISSN: 1549-3296, DOI: 10.1002/jbm.a.35284 *
SUMITKUMAR JAGANI ET AL: "Effects of phenol and natural phenolic compounds on biofilm formation by Pseudomonas aeruginosa", BIOFOULING: THE JOURNAL OF BIOADHESION AND BIOFILM RESEARCH, vol. 25, no. 4, 3 March 2009 (2009-03-03), GN, pages 321 - 324, XP055451744, ISSN: 0892-7014, DOI: 10.1080/08927010802660854 *

Also Published As

Publication number Publication date
LT3630092T (lt) 2022-06-27
US20200121638A1 (en) 2020-04-23
EP3630092A1 (en) 2020-04-08
CA3061568A1 (en) 2018-12-06
US20200360339A1 (en) 2020-11-19
ES2919423T3 (es) 2022-07-26
CL2019003254A1 (es) 2020-07-03
US11234958B2 (en) 2022-02-01
MA48936B1 (fr) 2022-08-31
CN110650737A (zh) 2020-01-03
BR112019023962A2 (pt) 2020-06-09
PL3630092T3 (pl) 2022-09-12
HUE059185T2 (hu) 2022-10-28
HRP20220808T1 (hr) 2022-09-30
AU2018275487A1 (en) 2019-11-07
MA48936A (fr) 2020-04-08
GEAP201815201A (it) 2020-07-27
EA201992190A1 (ru) 2020-09-03
BR112019023962A8 (pt) 2022-07-05
RS63347B1 (sr) 2022-07-29
US20210228541A1 (en) 2021-07-29
GEP20207179B (en) 2020-11-10
AU2018275487B2 (en) 2024-03-14
SI3630092T1 (sl) 2022-08-31
CA3061568C (en) 2024-02-13
MX2019013559A (es) 2022-02-03
EP3630092B1 (en) 2022-04-13
DK3630092T3 (da) 2022-06-20
WO2018219862A1 (en) 2018-12-06
PT3630092T (pt) 2022-06-02

Similar Documents

Publication Publication Date Title
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3497086T3 (da) Aminopyrimidin-SSAO-inhibitorer
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3456787T3 (da) Vandbaseret coatingformulering
DK3634377T3 (da) Farmaceutisk formulering
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
IT201700057079A1 (it) Batterioterapia a base di composizioni batteriche per il trattamento di malattie neurodegenerative
MA49006A (fr) Inhibiteurs d'ip6k
IL271550B (en) A cyclic coumarin-like compound as a mek inhibitor and its use
DK3710715T3 (da) Kugleleje
EP3471712A4 (en) ALDH SMALL MOLECULE INHIBITORS AND USES THEREOF
DK3601277T3 (da) Farmaceutisk formulering
IT201700058311A1 (it) Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
DK3712162T3 (da) Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf
DK3595442T3 (da) Mikroindkapslede nitrifikationsinhibitorsammensætninger
IT201900020350A1 (it) Formulazione orodispersibile di vardenafil
ES1280690Y (es) Mueble promocional
ES1229045Y (es) Base rodante autoportante portacargas
SG11202102727RA (en) Immunoproteasome inhibitor formulation
IT201900024310A1 (it) Dispositivo di erogazione
IT201700033519A1 (it) Attrezzo per tinteggiatura e relativo kit
UA40284S (uk) Білборд
PL3606515T3 (pl) Preparat inhibitora STAT3
UA38190S (uk) Графічне зображення «міні»